Loading
A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting.
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) is a phase 3 interventional study registered as NCT07431827, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013). Planned enrolment is 400 participants (estimated). The study started in 2026-03-18 and primary completion is expected in 2039-10-26. No results have been posted on ClinicalTrials.gov.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Resectable stage I to III non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).